What is SpectronRx?
SpectronRx specializes in the development, labeling, production, and global supply of therapeutic and diagnostic isotopes and radiopharmaceutical products. Its state-of-the-art facilities are designed for good manufacturing practice (GMP) compliance, enabling the support of advanced radioligand therapies and diagnostic drugs crucial for precision medicine and nuclear medicine applications. The company emphasizes scientific rigor, robust quality systems, and integrated services to assist partners in navigating complex regulatory pathways and scaling manufacturing operations for novel radiopharmaceuticals.
How much funding has SpectronRx raised?
SpectronRx has raised a total of $85M across 1 funding round:
Unspecified
$85M
Unspecified (2026): $85M with participation from OrbiMed
Key Investors in SpectronRx
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various stages of development, from early-stage ventures to established organizations, with a focus on innovation and market dynamics.
What's next for SpectronRx?
This substantial capital infusion, particularly the recent strategic investment, positions SpectronRx for accelerated growth and expanded operational capacity. The company is poised to further solidify its standing as a key player in the radiopharmaceutical CDMO sector, likely focusing on enhancing its manufacturing capabilities, expanding its service offerings, and potentially broadening its global supply chain network. This backing will be instrumental in supporting the development and commercialization of next-generation radioligand therapies and diagnostic agents, contributing significantly to the precision medicine landscape.
See full SpectronRx company page
